There are two solutions that are first to launch: DoubleJump™ Interchange, aimed at breaking down barriers for ecosystem collaboration, data integration and analysis; and Bodylogical™ from DoubleJump Health™, which will help predict chronic health outcomes at an individual and population level.

"We believe that in order to thrive in the New Health Economy™, businesses need more than a competitive edge. They must accelerate — even leapfrog — innovation. And that’s where DoubleJump Health™ comes in," said Kelly Barnes, partner, PwC Health Industries practice leader. "PwC’s investment in this area is game-changing for our clients and the healthcare industry in order to meet the complex challenges of the future."

DoubleJump™ Interchange is a revolutionary platform that enables traditional and non-traditional healthcare stakeholders to connect into a cloud-based interchange to share data, information, research and best practices across an enterprise or between organizations. This is important as all of the players in the health value chain need to be able to effectively connect data to achieve better outcomes.

While many talk about the possibilities of big data in healthcare, DoubleJump™ Interchange brings together the right partners for a purposeful exchange of information to improve the health of consumers.

For example, DoubleJump™ Interchange can help connect the dots between a patient’s wearable device data collected at home, to their vital signs taken at a retail clinic, to their historical health data stored with their primary care doctor.

This improved access to a patient’s longitudinal health data is important during a time when, according to PwC’s Health Research Institute, 81% of consumers are open to non-traditional care delivery, such as telehealth or retail clinics1. Yet, 48% of physicians believe that non-traditional care settings have had a negative impact on care coordination2. Thus, there is work to do to prove to physicians the value of accurate and reliable integrated health data in improving care delivery.

"Our complex healthcare system suffers from too many data siloes, a lack of patient data transparency, and an inability of an expanded care team to collaborate on behalf of a patient," said Mark Mynhier, principal, PwC Health Industries. "DoubleJump™ Interchange breaks down barriers between traditional and nontraditional healthcare stakeholders, allowing more effective care team collaboration and enabling anytime, anywhere care that meets the needs of chronic disease patients."

The second offering, Bodylogical™ from DoubleJump Health™, is a scientifically developed digital model of the human body that enables true-life simulations to predict the likely progression of chronic diseases in the future based on today’s actions and interventions.

By using Bodylogical™, pharmaceutical companies, providers, payers, employers, researchers and consumers can better understand how interventions impact individual patients or patient populations in order to become healthier faster and less expensively. This is critical as each year, chronic diseases cause 70% of deaths in the U.S.3 and account for 86% of the nation’s $3.2 trillion in healthcare spending4.

"Big data – the industry’s most advanced, current decision-making tool – is backward looking. It enables statistical models of the past outcomes of populations to make broad predictions about future ones. With Bodylogical™, we can go beyond big data and look forward to show the impact of health choices before they are made," said Paul D’Alessandro, principal, PwC Health Industries.

Bodylogical™ mirrors the system of connected physiological components in the human body, focused on major areas such as circulatory, respiratory, digestive, endocrine and renal, which are most effected by chronic diseases. Put together, PwC can create a "virtual consumer" that can be manipulated to see how one change in the body impacts other systems and overall health.

For example, it can show the impact sleep and exercise have on a person’s risk of developing diabetes over time. This service can enable payers to identify at-risk individuals and populations to predict and mitigate negative outcomes; pharmaceutical companies to run faster and more efficient clinical trials with greater certainty about their results; and it can connect to a range of existing health technologies, even consumer-level mobile devices and wearables, to help consumers and the entire health community understand the impact of decisions on overall health.